EUVIMEDOpdag EUVIMED
Crossref

Arginine Polymer-Based Nanoplatform Facilitates Oral Co-Delivery of Antibody/Antigen for Robust Oral Immunotherapy in Orthotopic Colon Cancer

Yali Zhuang, Liying Wang, Chunyuan Xie, Ruoxi Yang, Minghui Li, Chunlei Dai, Yongxiang Di, Mengfang Yuan, Tong Tong, Tianren Zhang, Xinru You, Xiaojun Xia and 1 more

ACS Nano · 2026

DOI: 10.1021/acsnano.6c08006 ↗

At a glance

Journal article in ACS Nano, 2026. Written by Yali Zhuang and 12 co-authors. Institution: Bioscience and Biomedical Engineering Thrust, The Hong Kong University of Science and Technology (Guangzhou), Nansha, Guangzhou 511400, China. Major MEDLINE topics: Immunotherapy, Colonic Neoplasms, Arginine, Ovalbumin. Cited 2 times so far (Crossref); 59 references. Funded by: National Key Research and Development Program of China, National Natural Science Foundation of China.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Immune checkpoint blockade and therapeutic cancer vaccines have transformed cancer treatment, yet their clinical application in colorectal cancer remains constrained by the lack of efficient oral delivery strategies for biomacromolecules such as antibodies and protein antigens. Here, we report a smart oral immunotherapy strategy that enables the codelivery of programmed death-ligand 1 antibody (anti-PD-L1) and ovalbumin (OVA) antigen for localized colorectal cancer treatment through an arginine-based polymeric nanoplatform. A biosafe cationic arginine-derived polymer (2A6S) was rationally engineered to electrostatically load both antibody and antigen cargos, while an enteric polymer coating (EudragitL100) protected the nanocomplexes from gastric degradation and ensured intestinal release. This dual-protective oral platform (EAPO NPs) achieved efficient colon lesion delivery and significantly enhanced local antitumor immune activation in an orthotopic MC38-OVA colorectal tumor model. Encouragingly, oral administration of EAPO NPs induced 53.34% tumor inhibition using only twice the antibody/antigen dosage compared with systemic injection, while substantially reducing potential systemic immunotoxicity. By integrating immune checkpoint blockade with antigen-specific immune priming through a single oral nanoplatform, this work establishes a simple, safe, and effective strategy for localized intestinal immunotherapy, which could be applicable to colorectal cancer and other colon-associated diseases.

Subjects

MeSH terms (MEDLINE)

ImmunotherapyColonic NeoplasmsArginineOvalbuminNanoparticlesPolymersAntigensAnimalsAdministration, OralMiceCell Line, TumorHumansFemalePolymethacrylic Acids

Author keywords

arginine-based poly(ester amide)simmunotherapyoral deliveryorthotopic colorectal tumorsprotein delivery

Substances

ArginineOvalbuminPolymersAntigensPolymethacrylic Acids

Authors and institutions

  • Bioscience and Biomedical Engineering Thrust, The Hong Kong University of Science and Technology (Guangzhou), Nansha, Guangzhou 511400, China.
  • State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center…
  • Department of Anesthesiology, General Hospital of Southern Theatre Command of PLA, Guangzhou 510010, China.
  • Department of Hematology, the Seventh Affiliated Hospital of Sun Yat-sen University, Shenzhen 518107, China.
  • Center for Nanomedicine and Department of Anesthesiology, Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts 02115, United States.
  • Division of Life Science, the Hong Kong University of Science and Technology, Hong Kong, SAR 999077, China.

ORCID profiles: Jun Wu

Funding

  • National Key Research and Development Program of China
  • National Natural Science Foundation of China

Cite

APA

Zhuang, Y., Wang, L., Xie, C., Yang, R., Li, M., Dai, C., Di, Y., Yuan, M., Tong, T., Zhang, T., You, X., Xia, X., & Wu, J. (2026). Arginine Polymer-Based Nanoplatform Facilitates Oral Co-Delivery of Antibody/Antigen for Robust Oral Immunotherapy in Orthotopic Colon Cancer. ACS Nano. https://doi.org/10.1021/acsnano.6c08006

Vancouver

Zhuang Y, Wang L, Xie C, Yang R, Li M, Dai C, et al. Arginine Polymer-Based Nanoplatform Facilitates Oral Co-Delivery of Antibody/Antigen for Robust Oral Immunotherapy in Orthotopic Colon Cancer. ACS Nano. 2026. doi:10.1021/acsnano.6c08006

BibTeX
@article{Zhuang2026,
  author = {Zhuang, Yali and Wang, Liying and Xie, Chunyuan and Yang, Ruoxi and Li, Minghui and Dai, Chunlei and Di, Yongxiang and Yuan, Mengfang and Tong, Tong and Zhang, Tianren and You, Xinru and Xia, Xiaojun and Wu, Jun},
  title = {Arginine Polymer-Based Nanoplatform Facilitates Oral Co-Delivery of Antibody/Antigen for Robust Oral Immunotherapy in Orthotopic Colon Cancer},
  journal = {ACS Nano},
  year = {2026},
  doi = {10.1021/acsnano.6c08006}
}
Start for free →